Genesis Research Group unveils enhanced US market access data analytics
November 21, 2024 |
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities to inform US market access strategy. Alongside this, Genesis also announces the appointment of Ki Park as Vice President, Market Access Strategy & Analytics.
This latest development further enhances Genesis Research Group’s integrated, dynamic approach to market access by combining the power of real-world data analytics with accelerated insights from the RPR Platform, which connects to 3,500+ stakeholders across 65+ countries. This unique integration of comprehensive stakeholder intelligence, real-world data analytics, and a differentiated engagement model provides life sciences companies with the rigorous and validated evidence required to enable timely strategic decisions with unprecedented confidence.
Ki Park brings with him over 20 years of US market access experience. His expertise in data analytics and market access will play a crucial role in enabling clients to leverage data and market intelligence to optimize access, from pre-launch through loss of exclusivity, by effectively navigating current and future market trends.
Ki Park, Vice President, Market Access Strategy & Analytics, commented: “Genesis Research Group helps its clients to innovate differently, and I am excited to join the business at a pivotal stage as it expands its capabilities and service offerings.
“The integration of real-world data analytics with the capabilities of RPR™ in the areas of contracting strategy, market assessment, patient affordability program optimization and healthcare policy impact will significantly enhance our clients’ ability to navigate the US market landscape, providing them with validated evidence-based insights necessary for success in today’s competitive environment. Alongside our unique proficiency in gaining insights from relevant stakeholders, Genesis has a superior ability to bolster that information with data, demonstrating what is happening in the real world quickly and efficiently.”
The company’s enhanced access and pricing capabilities deliver key insights on:
- Market potential for a potential launch product or new indication by analyzing the patient journey and assessing the barriers launch products might face by leveraging data analytics coupled with stakeholder input.
- Payer perceptions on product positioning and associated rebate levels can be combined with payer segmentation analytics to understand the opportunity to move share by payers’ ability to control product utilization.
- Patient access and avenues to optimize co-pay assistance programs leveraging within therapeutic area patients’ response to out-of-pocket costs and understand stakeholders’ views on the necessity and impact of such programs.
- Impact of IRA on patient access, leveraging real-world data layered with payer perceptions to assess and test potential scenarios.
David W. Miller, Chief Executive Officer of Genesis Research Group, said: “This expanded offering reflects our commitment to providing our US market access clients with rigorous, actionable insights that empower them to make more informed decisions. By integrating analytics capabilities within our existing framework, we are enhancing our ability to support clients at every stage of their market access journey. On behalf of the whole organization, I warmly welcome Ki and look forward to utilizing his wealth of expertise within the US market access and data analytics landscape.”
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group’s recent expansion of its real-world data…
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural…
Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act
To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to…
Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication
We are pleased to share that The Evidence Base have carried out a ‘deep dive’ into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights…
Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online
Genesis Research Group’s poster ‘Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey’ was recently named as…
Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group
A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition…
Genesis Research Group unveils enhanced US market access data analytics
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities…
Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers
Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.
Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program
Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life…
Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’
ITN Business invited Genesis Research Group to contribute to a news style programme ‘Advancing Healthcare’ featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one…